Cargando…
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
BACKGROUND: PARP inhibitors are active in various tumour types beyond BRCA-mutant cancers, but their activity and molecular correlates in colorectal cancer (CRC) are not well studied. METHODS: Mutations and genome-wide mutational patterns associated with homologous recombination deficiency (HRD) wer...
Autores principales: | Smeby, Jørgen, Kryeziu, Kushtrim, Berg, Kaja C.G., Eilertsen, Ina A., Eide, Peter W., Johannessen, Bjarne, Guren, Marianne G., Nesbakken, Arild, Bruun, Jarle, Lothe, Ragnhild A., Sveen, Anita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452640/ https://www.ncbi.nlm.nih.gov/pubmed/32799124 http://dx.doi.org/10.1016/j.ebiom.2020.102923 |
Ejemplares similares
-
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019) -
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019) -
The expressed mutational landscape of microsatellite stable colorectal cancers
por: Sveen, Anita, et al.
Publicado: (2021) -
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
por: Kryeziu, Kushtrim, et al.
Publicado: (2021) -
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
por: Bruun, Jarle, et al.
Publicado: (2018)